Is Peyronie’s an IgG4-related disease?

Mehmet Solakhan¹, Bünyamin Kısacık²

Abstract

Objective: We believe that IgG4 may have a role in the pathogenesis of Peyronie’s disease (PD), and this role could be particularly beneficial for developing new strategies; therefore, we aimed to investigate the role of IgG4 in PD.

Methods: This study included 3 groups with a total of 139 subjects: (I) PD group (n=61), (II) control group (n=48), and (III) benign prostatic hyperplasia (BPH) group (n=30). IgG4 measurement was performed using the enzyme-linked immunosorbent assay. Plaque size, penile curvature, and the presence of concomitant impotence were evaluated in the PD group. Impotence was assessed based on the International Index of Erectile Function (IIEF).

Results: A significant difference was observed between the PD and control groups and between the PD and BPH groups with regard to IgG4 levels, while no significant difference was found between the BPH and control groups (p=0.0001, p=0.002, and p=0.07, respectively). The IgG4 levels were significantly higher in the PD than in the other groups. The cutoff value determined between the groups was 87.5, 82, and 31.5, respectively. Mean plaque size was 2.0±1.01 cm, and a significant relationship was found between plaque size and IgG4 concentration (p=0.02). Mean penile curvature was 35.6±25.1°, and a significant relationship was found between penile curvature of >60° and IgG4 concentration (p=0.001). Mean IIEF score was 19 (range, 7-25). Moreover, no significant relationship was found between erectile dysfunction and IgG4 concentration. Penile pain was present in 24 (39.3%) patients with PD.

Conclusion: The IgG4 levels were significantly increased in patients with PD, which implies that IgG4 may have a role in the pathogenesis of PD. This finding could be particularly beneficial for developing new strategies. Future studies with larger patient series are needed to substantiate our findings.

Keywords: Etiology of Peyronie disease, IgG4, IgG4 related disease, Peyronie disease

Introduction

Peyronie’s disease (PD) is a chronic disease of the tunica albuginea of the corpus cavernosum, characterized by excessive fibrosis and plaque formation, affecting 3%-13% of men (1). Although the exact etiology of PD remains unknown, the transforming growth factor beta 1 (TGF-ß1) is believed to play a role in the induction of collagen production by fibroblasts/myofibroblasts, thereby leading to dominant expression of type III collagen, which is often seen in inflammatory pathologies in the tunica albuginea, which is characterized by type I collagen expression (2). As a result, morphological problems, such as curvature, shortening, contraction, hourglass deformity, and notch defect, as well as functional problems, such as erectile dysfunction (ED), may occur. After PD begins to occur, it is divided into two phases: acute and chronic or stable phase. The most obvious symptom in the acute phase is pain during erection. An increase in the degree of curvature is observed. If the disease is found to remain unchanged for three months clinically, the patient should be considered to be in the stable phase. In some patients, spontaneous regression can be observed within the first year after diagnosis, while approximately 45% remain stable and 40% show progression (2).

Elevated serum IgG4 concentrations and lymphoplasmacytic infiltrate with IgG4-positive plasma cells are the hallmark features of IgG4-related disease (IgG4-RD). IgG4-RDs manifest dense lymphoplasmacytic infiltrations with a predominance of IgG4-positive plasma cells in the affected tissue, usually accompanied by some degree of fibrosis and often by obliterator phlebitis and an increased number of eosinophils. Although the pathogenesis causing these manifestations remains unclear, IgG4 expression is believed to be induced by various species of pathogens, thereby preventing innate immunity and ultimately leading to persistent inflammation (3). Moreover, when inflammation becomes chronic, it may result in fibrosis (4). This study aimed to investigate the relationship between PD and IgG4. The role of IgG4 in PD pathogenesis has been investigated. There is very little data in the literature on this subject.
Methods

The study protocol was approved by the Sanko University local ethics committee (2019/05-03). Written informed consent was obtained from the patients who participated in this study. This study was conducted between April 2015 and December 2019. This study included 3 groups with a total of 139 subjects: (i) PD group (n=61), (ii) control group (n=48), and (iii) benign prostatic hyperplasia (BPH) group (n=30). This study started with 89 patients with PD. It was found that 9 of them had diabetes mellitus (DM), 6 had hypertension (HT), 4 had coronary artery disease (CAD), 6 had rheumatological diseases and chronic inflammation, and 3 had cancer. These patients were excluded from the study. This study was completed with 61 patients with PD. The BPH group started work with a total of 52 patients. Among these, 6 patients had DM, 5 had HT, 2 had CAD, 6 had different chronic diseases, and 3 had acute infectious diseases. These patients were excluded from the study. This study was completed with 61 patients with PD. Fasting serum samples were obtained from each participant and were stored at -80°C. IgG4 measurement was performed using the enzyme-linked immunosorbent assay. PD was diagnosed based on patient history and physical examination findings. On physical examination, presence of plaques, plaque size, and the degree of penile curvature were recorded. Differential diagnosis was established using the PD questionnaire (5). The control group included voluntary healthy subjects with no known diseases and no active drug use. The BPH group consisted of voluntary patients with BPH and with no systemic diseases who had been recently diagnosed and initiated on drug therapy in our urology outpatient clinic. In the PD group, plaque size, penile curvature, and the presence of concomitant impotence were recorded for each patient. Additionally, plaque localization was assessed (Table 1). The relationship between plaque size and IgG4 concentration (p=0.001). Although the IgG4 levels were higher in the BPH group than in the control group, no significant difference was found. The cutoff value determined between the patient and control groups was found to be 87.50 (Figure 2). The cutoff value determined between the patient and BPH groups was found to be 82 (Figure 3). The cutoff value determined between BPH and control groups was found to be 31.5 (Figure 4). The mean plaque size was 2.0±1.01 cm, and the plaques were mostly localized in the dorsal, dorsolateral, ventral, ventrolateral, lateral, and septal aspects of the penis. A significant relationship was detected between plaque size and IgG4 concentration (p=0.02). Mean penile curvature was 35.6±25.1°, and a significant relationship was found between penile curvature of >60° and IgG4 concentration (p=0.001). In terms of impotence, mean IIEF score was 19 (range, 7-25). Moreover, no significant relationship was found between ED and IgG4 concentration. Penile pain was present in 24 (39.3%) patients with PD, while no pain was reported by 37 (60.7%) patients.

Table 1. Clinical features of patients with Peyronie’s disease.

| Group 1 (n=61) | Plaque size (cm) | 2.0±1.01 |
|---------------|-----------------|----------|
| Plaque localization (n) | Dorsal/dorsolateral | 19 (31.1%) |
| | Lateral (right/left) | 10 (16.4%) |
| | Ventral/ventrolateral | 21 (34.4%) |
| | Septum | 11 (18.1%) |
| Duration of PD (month) | 14.5±7.1 |
| Curvature angle (°) | <60° (n) | 41 (67.2%) |
| | >60° (n) | 20 (32.8%) |
| Pain | yes | 24 (39.3%) |
| | no | 37 (60.7%) |
| IIEF score | 19 (725) |

Table 2. Results between the groups.

| | Peyronie’s disease (n=61) | Healthy control (n=48) | Benign prostatic hypertrophy (n=30) | p |
|---|---------------------|-------------------|-----------------------------|---|
| Age (year) | 52±13.3 | 49±13.1 | 55±8.7 | 0.397* |
| IgG4 (mg/dL) | 101.5 (15-235) | 30.5 (4-114) | 61 (14-140) | 0.0001b |
| BMI (kg/m²) | 24.37±3.5 | 25.3±2.8 | 26.6±3.1 | 0.865c |

*Kruskal-Wallis rank sum test. Between groups I and II, 0.397; between groups I and III, 0.08; and between groups II and III, 0.12. **Mann-Whitney U test. Between groups I and II, 0.0001; between groups I and III, 0.002; and between groups II and III, 0.07.

Main Points

- Peyronie’s disease may be IgG4 related disease.
- Treatment may give better results in patients with IgG4 positive.
- In some patients with PD, IgG4 may be responsible for the etiology.

Eur J Rheumatol 2021; 8(1): 27-30
The results indicated that the IgG4 levels were higher in the PD group than the control group. Additionally, a significant relationship was found between plaque size, penile curvature, and IgG4 concentration.

Although there have been numerous studies investigating the pathophysiological mechanisms in PD, the exact mechanism of PD remains unknown. Lucattelli et al. (6) induced a rat model of spontaneous PD and reported that hypoxia-inducible factor-1 (HIF-1) and HIF-1 target genes may play an important role in the pathogenesis of PD. El-Sakka et al. (8) suggested that microtrauma induces TGF-β1 expression, thereby leading to inflammation and fibrosis, ultimately resulting in typical manifestations of PD, including plaque formation and penile curvature (7). Similarly, Zimmerman et al. (9) found that serum TGF-β1 levels were significantly elevated, and the tumor necrosis factor-a and interleukin-6 (IL-6) levels were significantly decreased in patients with PD when compared with control subjects. Another study reported that nitric oxide synthase was reduced by reactive oxygen species (10). In a previous systematic review, Ventimiglia et al. (11) found a significant relationship between PD and autoimmune diseases and also suggested that there was a significant relationship between PD and human leukocyte antigens, and hence, a relationship between PD and autoimmune diseases. Additionally, recent genetic studies have also indicated that the Wnt Family Member 2 (WNT2) locus may play a role in increased susceptibility to PD (12).

Accumulating evidence suggests that there are numerous immune-mediated mechanisms responsible for fibro-inflammatory processes in IgG4-RD. Moreover, autoimmune and infectious agents may act as potential immunological triggers of the disease. Various ILs, including IL-4, IL-5, IL-10, and IL-13, and transforming growth factor β (TGF-β) are overexpressed in IgG4-RD as a result of the activation of T-helper 2 (Th2) cells and regulatory T (Treg) cells. These cytokines lead to increased eosinophilia and enhanced production of both IgG4 and IgE and also contribute to the progression of fibrosis, which is the hallmark of IgG4-RD. Massive infiltration of inflammatory cells results in organ injury. Additionally, epithelial injury arises from tissue inflammation and immune complex formation (13). Yamamoto et al. (4) suggested that the pathogenesis of IgG4-RD is characterized by Th2-cell-dominant immune responses and abundant infiltration of Treg cells, which produce IL-10, into the organs involved. The authors also noted that IgG4-RD is also predominantly associated with a Th2-cell cytokine profile and that Treg cells and TGF-β produced by IL-10 are associated with elevated serum IgG4 levels and fibrosis (4). Taken together, these findings implicate that there are shared TGF-β-mediated mechanisms between PD and IgG4-RD. To our knowledge, there has been no study investigating the relationship between IgG4-RD and PD, and there are several case reports documenting elevated IgG4 level in cases of Zoon balanitis (14). In this study, IgG4 levels were significantly higher in patients with PD than in the control subjects, with 22 (36%) of the patients with PD having an IgG4 level above the upper limit (235 mg/dL) (range, 135-235). In contrast, a significant relationship was found between elevated IgG4 levels and plaque size and penile curvature, which could provide useful information regarding the severity of fibrosis in patients with elevated IgG4 levels.

**Figure 1.** Distribution of IgG4 levels between the groups.

**Figure 2.** Patient and control group ROC analysis (cut-off value: 87.50). The area under the curve for IgG4 is 0.834 (95% CI; 0.758-0.909).

**Figure 3.** Patient and BPH group ROC analysis (cut-off value: 82). The area under the curve for IgG4 is 0.719 (95% CI; 0.595-0.807).

**Figure 4.** BPH and Control group ROC analysis (cut-off value: 31.5). The area under the curve for IgG4 is 0.701 (95% CI; 0.595-0.807).
In our study, the IgG4 levels were significantly higher in the other patient group (BPH group) when compared with the control group. To the best of our knowledge, the IgG4 levels have not been evaluated in patients with BPH. Nonetheless, there are several studies reporting on IgG4-related prostatitis in which the patients were detected with serious lower urinary tract symptoms, normal prostate-specific antigen levels, and elevated IgG4 levels. Moreover, the patients were also detected with lymphoplasmacytic infiltration, storiform fibrosis, and diffuse IgG4-positive plasma cells in immunohistochemical examination (15-17). In this study, the IgG4 levels were significantly higher in the patients with PD when compared with those with BPH.

Since this study had a small patient population, no immunohistochemical analysis of tissues was performed, and no information was provided regarding the long-term follow-up and treatment processes of the patients.

In conclusion, we believe that IgG4 may have a role in the pathogenesis of PD, and this role could be particularly beneficial for developing new strategies. Additionally, we suggest that IgG4 should be considered in idiopathic patients. Future studies with larger patient series are needed to substantiate our findings.

Ethics Committee Approval: Ethics committee approval was received for this study from the Ethics Committee of Sanko University (Approval Date: 2019; Approval Number: 2019/05-03).

Informed Consent: Written informed consent was obtained from the patients who participated in this study.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept - M.S., BK; Design - M.S.; Supervision - M.S., BK; Resources - M.S.; Materials - M.S.; Data Collection and/or Processing - M.S.; Analysis and/or Interpretation - M.S., BK; Literature Search - M.S.; Writing Manuscript - M.S.; Critical Review - M.S., BK.

Conflict of Interest: The authors have no conflict of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.

References
1. Sherer BA, Warrior K, Levine LA. 2013-2014 update in Peyronie’s disease management. Curr Urol Rep 2014; 15: 459. [Crossref]
2. Toktaş C, Turan T. Peyroni hastalığının medikal-minimal invaziv tedavisi: Klavuzlar eşliğinde güncellemesi. Androloji Bülteni 2016; 18: 69-73.
3. Umehara H, Nakajima A, Nakamura T, Kawanami T, Tanaka M, Dong L, et al. IgG4-related disease and its pathogenesis-cross-talk between innate and acquired immunity. Int Immunol 2014; 26: 585-95. [Crossref]
4. Yamamoto M, Takahashi H, Shinomura Y. Mechanisms and assessment of IgG4-related disease: Lessons for the rheumatologist. Nat Rev Rheumatol 2014; 10: 148-59. [Crossref]
5. Hellstrom WI, Feldman R, Rosen RC, Smith T, Kaufman G, Tursi J. Bother and distress associated with Peyronie’s disease: Validation of the Peyronie’s disease questionnaire. J Urol 2013, 190: 627-34. [Crossref]
6. Lucattelli M, Lunghi B, Fineschi S, Miore V, Bianca RV, Longo N, et al. A new mouse model of Peyronie’s disease: An increased expression of hypoxia-inducible factor-1 target genes during the development of penile changes. Int J Bioch Cell Biol 2008; 40: 2638-48. [Crossref]
7. Haag SM, Hauck EW, Szaudening-Kirchner C, Diemer T, Cha ES, Weidner W, et al. Alterations in the transforming growth factor (TGF)-β pathway as a potential factor in the pathogenesis of Peyronie’s disease. Eur Urol 2007; 51: 255-61. [Crossref]
8. El-Sakka AI, Hassoba H. An animal model of Peyronie-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 1997; 158: 2284-90. [Crossref]
9. Zimmermann RP, Feil G, Bock C, Hoeltl L, Stenzl A. Significant alterations of serum cytokine levels in patients with Peyronie’s disease. Int Braz J Urol 2008; 34: 457-66. [Crossref]
10. Ferrini MG, Vernet D-C. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 2002; 6: 283-94. [Crossref]
11. Ventimiglia E, Capogrosso P, Colicchia M, Boeri L, Serino A, La Croce G, et al. Peyronie’s disease and autoimmunity—A real-life clinical study and comprehensive review. Sex Med 2015; 12: 1062-9. [Crossref]
12. Dolmans GH, Werker PM, de Jong U, Nijman RJ, LifeLines Cohort Study, Wijmenga C, et al. WNT2 locus is involved in genetic susceptibility of Peyronie’s disease. J Sex Med 2012; 9: 1430-4. [Crossref]
13. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366: 539-51.
14. Aggarwal N, Parwani AV, Ho J, Cook JR, Swardlow SH. Plasma cell (Zoon) balanitis: Another inflammatory disorder that can be rich in IgG4-positive plasma cells. Am J Surg Pathol 2014; 38: 1437-43. [Crossref]
15. Buijs J, de Buy Maillette, Wenniger L, van Leenders G, Verheij J, van Onna I, et al. Immunoglobulin G4-related prostatitis: A case-control study focusing on clinical and pathologic characteristics. Urology 2014; 83: 521-6. [Crossref]
16. Hart PA, Smyrk TC, Chari ST. IgG4-related prostatitis: A rare cause of steroid-responsive obstructive urinary symptoms. Int J Urol 2013, 20: 132-4. [Crossref]
17. Bourlon MT, Sánchez-Avila M, Chablé-Monette R, Arceo-Olaiz R. IgG4-related autoimmune prostatitis: Is it an unusual or underdiagnosed manifestation of IgG4-related disease? Case Rep Urol 2013, 295472. [Crossref]